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Abstract
Aberrant epidermal growth factor receptor (EGFR) signaling is common in cancer. Increased expression of wild type
and mutant EGFR is a widespread feature of diverse types of cancer. EGFR signaling in cancer has been the focus of
intense investigation for decades primarily for two reasons. First, aberrant EGFR signaling is likely to play an important
role in the pathogenesis of cancer, and therefore, the mechanisms of EGFR-mediated oncogenic signaling are of in-
terest. Second, the EGFR signaling system is an attractive target for therapeutic intervention. EGFR gene amplifica-
tion and overexpression are a particularly striking feature of glioblastoma (GBM), observed in approximately 40% of
tumors. GBM is the most common primary malignant tumor of the central nervous system in adults. In approximately
50%of tumorswith EGFR amplification, a specific EGFRmutant (EGFRvIII, also known as EGFR type III, de2-7,ΔEGFR)
can be detected. This mutant is highly oncogenic and is generated from a deletion of exons 2 to 7 of the EGFR gene,
which results in an in-frame deletion of 267 amino acids from the extracellular domain of the receptor. EGFRvIII is
unable to bind ligand, and it signals constitutively. Although EGFRvIII has the same signaling domain as the wild type
receptor, it seems to generate a distinct set of downstreamsignals thatmay contribute to an increased tumorigenicity.
In this review,wediscuss recent progress in key aspects ofEGFRsignaling inGBM, focusingonneuropathology, signal
transduction, imaging of the EGFR, and the role of the EGFR in mediating resistance to radiation therapy in GBM.
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Introduction
The epidermal growth factor receptor (EGFR) induces proliferation
and/or has a trophic effect on multiple cell types [1]. The EGFR is ex-
pressed at high levels in various types of cancer, suggesting a role in the
pathogenesis ofmultiple cancer types [2]. Furthermore, there is substan-
tial experimental evidence supporting a causal role for aberrant EGFR
signaling in cancer pathogenesis and resistance to treatment [3]. EGFR
gene amplification and overexpression are a striking feature of glioblas-
toma (GBM) but are rare in low-grade gliomas, suggesting a causal role
for aberrant EGFR signaling in the pathogenesis of GBM. The most
common EGFR mutant is named EGFRvIII (EGFR type III, EGFR-
vIII, de2-7, ΔEGFR) [4,5]. This mutant is generated from a deletion
of exons 2 to 7 of the EGFR gene, which results in an in-frame deletion
of 267 amino acids from the extracellular domain of the receptor.
EGFRvIII is unable to bind ligand, and it signals constitutively. It is
important to note that EGFRvIII is usually coexpressed with the wild
Address all correspondence to: AmynA.Habib,MD, 4500 South Lancaster Rd,MC151,
Dallas, TX 75216. E-mail: Amyn.Habib@UTSouthwestern.edu
1A.H. is supported by National Institutes of Health grant R01NS062080-01A2 and
D.Z. is supported by National Institutes of Health grant 1R21 CA141348-01A1.
S.B is supported by grants from National Aeronautics and Space Administration
(NNA05CS97G and NNX10AE08G) and from the Cancer Prevention and Research
Institute of Texas (RP100644).
Received 17 May 2010; Revised 7 June 2010; Accepted 8 June 2010
Copyright © 2010 Neoplasia Press, Inc. All rights reserved 1522-8002/10/$25.00
DOI 10.1593/neo.10688
www.neoplasia.com
Volume 12 Number 9 September 2010 pp. 675–684 675
type (wt) receptor in GBM [4,6]. Coexpression of ligand also has been
noted in tumors, suggesting that autocrine or paracrine loops contribute
to malignant progression [4,7–9]. There is substantial evidence suggest-
ing that EGFRvIII signaling plays a key role in gliomagenesis [3,10].
A number of studies have demonstrated that the EGFRvIII variant is
more tumorigenic than the wt receptor [11–15]. Increased EGFRvIII
expression may influence multiple aspects of tumor biology, including
survival, proliferation of cells, motility and invasiveness, and resistance
to treatment [13,16–19].
The EGFR signaling network thus presents an attractive target for
therapeutic intervention, and considerable effort is focused on trying
to inhibit the receptor in various types of cancer using antibodies, tyro-
sine kinase inhibitors (TKIs), or vaccines [20,21]. Anti-EGFR treatment
seems to be effective in patients with EGFR tyrosine kinasemutations in
lung cancer [22–25]. Cancer cells can become dependent on activated
oncogenes for their survival. This phenomenon has been called onco-
gene addiction. Whereas initial studies showed there is a low rate of re-
sponse to EGFRvIII inhibitors in GBMoverall [26], a subset of patients
with coexpression of EGFRvIII and PTEN seemed to be more respon-
sive to anti-EGFR therapy with Erlotinib (Tarceva) in GBM [27,28].
However, a subsequent study reported that the concomitant expres-
sion of EGFRvIII with PTEN was not predictive of improved survival
in patients treated with Erlotinib [26,29]. These findings suggest that
more complex molecular signatures associated with individual tumors
may need to be identified for clinically effective targeting of the EGFR
system in GBM. Furthermore, certain EGFR mutations, such as tyro-
sine kinase mutations found in lung cancer, may be more responsive
to TKI compared with GBM in which a different spectrum of EGFR
mutations is present.
Neuropathological Aspects of EGFR and
EGFRvIII in Glioma
Prevalence and Age Distribution
Overall, 36% to 40% of GBMs exhibit EGFR gene amplification
[30,31]. In a study of 30 GBMs, EGFR gene amplification was always
associated with immunohistochemical EGFR protein overexpression,
defined as strong plasma membrane or cytoplasmic immunopositivity
in most tumor cells, but 10% of GBMs with EGFR protein overexpres-
sion lacked EGFR gene amplification [32,33]. In our own series, 23
(36%) of 64 GBMs had EGFR gene amplification by chromogenic
in situ hybridization on a tissue microarray (Table 1). We evaluated
EGFR protein expression in these GBMs using the EGFR pharmDx
antibody (Dako, Carpinteria, CA) and following the interpretation
guidelines provided by the manufacturer. These interpretation guide-
lines, approved by the US Food and Drug Administration for identify-
ing colorectal cancer patients eligible for treatment with cetuximab,
only consider cell membrane staining to represent positive staining.
We found a strong, although imperfect correlation between EGFR gene
amplification status and EGFR gene expression (Table 1 and Figure 1).
Most GBMs (54%) overexpress wtEGFR protein and 31% over-
express both wtEGFR and EGFRvIII [34]. By immunohistochemistry
(IHC), EGFRvIII is present in 41%ofGBMswith EGFR amplification
[4]. A small proportion of GBMs (5%) may express EGFRvIII without
concomitant EGFR gene amplification, but such tumors, nevertheless,
always express high levels of wtEGFR [35]. EGFRvIII expression with-
out EGFR gene amplification is relatively uncommon, suggesting that
EGFR gene amplification may precede EGFRvIII mutation.
More than 90% of GBMs are primary GBMs, which arise without
evidence of a preceding lower-grade astrocytoma. Secondary GBMs
progress from lower-grade astrocytomas and tend to occur in younger
patients than primary GBMs (mean age, 45 vs 62 years) [31]. The
genetic profiles of primary and secondary GBMs are different and in-
clude a much higher prevalence of EGFR gene amplification and EGFR
overexpression in primary GBMs compared with secondary GBMs
(40% vs 8% and >60% vs <10%, respectively) [31].
The age distribution of patients with EGFR-amplified GBMs reflects
that of patients with primary GBMs. EGFR gene amplification is rare
in GBMs, occurring in patients younger than age 35. With increasing
patient age, EGFR amplification becomes more common. The median
age of patients with EGFR-amplified GBM is 62 years [31]. Pediatric
GBMs are rare and show genetic differences compared with adult
GBMs, including a much lower prevalence of EGFR amplification
(0%-5% vs 36%-40%) and EGFR protein overexpression (25% vs
>60%) in pediatric GBMs [36,37].
Histopathological Features
As suggested by the old name for GBM “glioblastoma multiforme,”
GBMs come in a number of histologic subtypes, including pleomorphic
cell GBM (26% of GBMs), gemistocytic GBM (25%) [38], GBMwith
oligodendroglioma component (15%) [39], small cell GBM (27%)
[30], gliosarcoma (2%) [40], and giant cell GBM (1%) [41], as well
mixed variants composed of more than one histologic pattern. GBM
with oligodendroglioma component includes both astrocytic and oligo-
dendroglial areas and, based on some studies, may be associated with a
more favorable prognosis [42]. According to the most recent World
Health Organization classification, GBM with oligodendroglioma
component is distinguished from anaplastic oligoastrocytoma based
on the presence of necrosis only in the former tumor [43]. Small cell
GBMs are highly cellular and cytologically monotonous neoplasms
with frequentmitoses [30] (Figure 1). Gliosarcomas are biphasic tumors
containing areas of malignant mesenchymal tumor (sarcoma) as well as
conventional GBM. Giant cell GBMs contain frequent extremely large,
multinucleated, and highly pleomorphic cells.
EGFR gene amplification is relatively common in small cell GBMs
(69%) [30,44] but rare in gliosarcomas (0%) [45] and giant cell GBMs
(6%) [46]. Similarly, wtEGFR and EGFRvIII expression is more com-
mon in small cell GBMs compared with non–small cell GBMs (83% vs
35% and 50% vs 21%, respectively) [44] (Figure 1). A subset of small
cell GBMs with EGFR amplification shows areas with oligodendroglial
histologic features, including round nuclei with perinuclear halos [44].
Given the evidence that the clinical behavior of such GBMs is similar
to conventional GBMs [44], we do not use the designation “GBMwith
oligodendroglioma component” for EGFR-amplifiedGBMswith oligo-
dendroglial features.
Table 1. Strong Correlation between EGFRGene Amplification Status and EGFR Protein Expression
at the Cell Membrane in Human GBMs (n = 64).
EGFR Amplification EGFR Protein Expression (IHC Score)
0 1+ 2+ 3+ Total
No 14 15 10 2 41
Yes, focal 1 1 1 3 6
Yes, diffuse 0 1 2 14 17
Total 15 17 13 19 64
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Distribution of Tumor Cells with EGFR Amplification
In some GBMs, almost all of the tumor cells have EGFR amplifica-
tion, but in other GBMs, the proportion of tumor cells with EGFR
amplification can vary from 10% to 60% in different areas of the same
tumor [47,48]. According to one study, EGFR amplified cells weremore
frequent near the edge of the tumor compared with the center [47], but
no such correlation was found in another study [48]. In our own series,
EGFR gene amplification was diffuse in 27% and focal in 9% of GBMs
(Table 1). Of the GBMs with strong (3+) EGFR protein expression
at the cell membrane, 74% showed diffuse EGFR gene amplification
(affecting most of the tumor cells), and an additional 16% had focal
EGFR gene amplification. Of the GBMs with no EGFR protein ex-
pression at the cell membrane (IHC score 0), none had diffuse EGFR
gene amplification and 7% had focal EGFR gene amplification.
Effect on Prognosis
Among GBMs (grade IVastrocytomas), EGFRvIII expression has no
effect on survival [35]. The prevalence of EGFRvIII expression in ana-
plastic astrocytomas (grade III astrocytomas) is much lower than in
GBMs (9% vs 31%) [35]. Like EGFR amplification, EGFRvIII expres-
sion in tumors diagnosed as anaplastic astrocytomas is predictive
of GBM-like clinical behavior [35,44]. Many of such anaplastic astro-
cytomas likely represent undersampled GBMs. Thus, EGFR gene
amplification is one of the genetic hallmarks of GBM. In diagnostic
neuropathology practice, identification of neoplastic astrocytes with
EGFR amplification by fluorescent or chromogenic in situ hybridi-
zation constitutes strong evidence that the tumor is a GBM, or at least
should be treated like a GBM, even when the histologic criteria for
GBM are not met because of the absence of necrosis and microvascular
proliferation in the biopsy. Several studies have shown that although
EGFR amplification and EGFR protein overexpression have no effect
on prognosis when patients of all ages are analyzed together, EGFR
amplification is associated with a worse prognosis among younger pa-
tients and with a more favorable prognosis among older patients (aged
>45, >55, or >60 years, depending on study) [47,49–52]. EGFR am-
plification does not preclude an unusually long survival, as 26% of
GBM patients surviving longer than 3 years have GBMs with EGFR
amplification [53].
Imaging of EGFR and Tumor Response to
Anti-EGFR Treatment
Given the importance of the EGFR signaling pathway in tumor ag-
gressiveness, treatment resistance, and poor prognosis in various tumor
types, in the past several years, a great deal of effort has been made in
developing molecular imaging approaches to noninvasively evaluate
EGFR status and therapeutic response to EGFR targeting agents. Spe-
cific EGFR targeting imaging probes have been developed for multiple
imaging modalities including positron emission tomography (PET),
single photon emission computed tomography (SPECT), optical imag-
ing, and magnetic resonance imaging (MRI). The ultimate goal of
in vivo imaging of EGFR is to enable clinicians to stratify the patients
who are likely to benefit fromEGFR targeting therapeutics andmonitor
treatment efficacy.
Figure 1. Small cell GBMs are highly cellular tumors composed ofmonomorphic cells with ovoid nuclei. Most small cell GBMs harbor EGFR
gene amplification, shown here by chromogenic in situ hybridization as innumerable red dots corresponding to EGFR gene copies in the
tumor cell nuclei. EGFR gene amplification is typically associated with strong cell membrane staining (arrows) for the EGFR protein by IHC,
although diffuse cytoplasmic staining is also seen. Gliosarcomas, which are characterized by a collagen-rich stroma, usually do not exhibit
EGFR gene amplification. Moderate cytoplasmic EGFR immunopositivity may be seen even in tumors without EGFR gene amplification, but
distinct cell membrane staining is rarely, if ever, present.
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Radiopharmaceuticals (PET and SPECT) for Imaging EGFR
Both PET and SPECT are nuclear medicine imaging techniques
involving introduction of radioactive tracer material into subjects and
detection of gamma rays emitted directly or indirectly from the tracer.
Because of the superb sensitivity and clinical applicability of PET and
SPECT imaging, development of radiotracers for imaging EGFR has
attracted intense interest. Two classes of PET or SPECT probes have
been developed by radiolabeling either ligands or antibodies against
extracellular EGFR binding domain or small molecule TKIs target-
ing intracellular receptor tyrosine kinase domain [54–56]. Among
the first class, usage of the natural EGFR ligand, EGF [57], or the anti-
bodies including the intact monoclonal antibody such as cetuximab
[58] or fragments of the antibodies such as F(ab′)2 or Affibody
[59,60] has been investigated. Attempts to develop small molecule re-
versible or irreversible TKI probes have been mainly focused on the
4-anilinoquinazoline class of compounds that had been originally devel-
oped for therapy [54]. Pal et al. [61] showed that 124I radiolabeled TKI
that irreversibly binds to the phosphorylated EGFR may be a surrogate
marker for EGFR activation. A wide variety of isotopes ranging from
short half-lives 11C and 18F to longer ones like 177Lu have been used to
label such anti-EGFR molecules. The rationale for choosing an isotope
relies mostly on its characteristics and pharmacokinetics, which should
typically have a half-life, ideally matching the biological half-life of the
end compound to maximize signal-to-noise ratio. For instance, longer
half-life radiotracers such as 177Lu (∼6 days) are useful in labeling a
whole antibody of EGFR that has longer clearance time, whereas the
shorter half-life ones like 11C (∼20 min) and 18F (∼2 h) are used in
labeling fragments of EGFR antibody, namely, Diabody or Affibody.
Comprehensive information about radiopharmaceuticals for imaging
EGFR can be found in the excellent review articles by Mishani et al.
[54] and Cai et al. [56]. In addition to EGFR overexpression, EGFR
mutations have been found in considerable numbers of cancer patients.
As discussed in this review, EGFRvIII is the most common and highly
oncogenic EGFR mutant in GBM, and imaging the status of EGFR-
vIII could be of great value in stratifying patients and monitoring treat-
ment in GBM. Takasu et al. [62] showed that 3C10 monoclonal
antibody, specifically recognizing EGFRvIII, labeled by technetium
Tc 99m (99mTc) significantly accumulated in the EGFRvIII-expressing
intracranial glioma xenografts in nude mice. Extensive preclinical work
on animal tumor models has been conducted to detect in vivo EGFR.
Most recently, Liu et al. [63] reported the first application of PET
EGFR imaging on humans, suggesting PD153035, a small molecule
TKI labeled with 11C, as a promising PET tracer.
Optical Imaging of EGFR Expression
The cheap, high-throughput optical imaging has been rapidly
adapted to cancer research [64]. In vivo fluorescence imaging depends
on fluorescence probes that emit light, which can be captured by a
charge-coupled device camera. Fluorescence imaging by using con-
jugates of the EGFR ligand, EGF, or anti-EGFR antibodies with fluoro-
phores or Quantum dots (QDs) has been investigated in vivo in the
detection of EGFR in various tumors of animal models [65–68]. Ke
et al. [65] applied EGF-Cy5.5 to assess EGFR expression and showed
that significantly higher fluorescent light intensity was detected in
EGFR+ than in EGFR− mammary tumors. In another study, Hama
et al. described a two-step activation process to visualize EGFR by ad-
ministering biotinylated cetuximab followed by neutravidin-fluorescent
conjugate. An ∼10-fold amplification of the optical fluorescence signal
was achieved in the EGFR+ tumors [66]. Long-wavelength fluoro-
phores such as near-infrared fluorescence has several advantages over
short-wavelength visible lights including deeper penetration owing to
less tissue absorption and scattering of light and minimal autofluores-
cence. Thus, using near-infrared fluorescence enables to image deep-
seated orthotopic tumors in small animal models. In the clinical setting,
optical imaging has recently emerged as an attractive approach to facili-
tate identification of infiltrative tumors and sentinel lymph node metas-
tases through endoscopy or during intraoperative visualization [69,70].
MRI Monitoring of Anti-EGFR Treatment
In contrast to more emphases on developing imaging probes to visu-
alize EGFR expression by PETor optical imaging,MRI has beenmostly
used to evaluate EGFR or anti-EGFR treatment response based on
conventional MRI parameters, namely, changes in T2-weighted or T1-
weighted contrast-enhanced signal intensity, which are believed to
reflect pathophysiological characteristics. However, a few studies have
demonstrated MRI’s capability of imaging EGFR expression based on
MRI contrast agents conjugated with anti-EGFR monoclonal antibody
or ScFvEGFR [67,71]. Applying MRI parameters to predict EGFR
amplification in GBM of patients was reported by Aghi et al. [72]. Sig-
nificantly higher T2/T1 ratio and T2 border sharpness coefficients was
found in the cohort of GBMwith amplified EGFR, whichmay correlate
with increased angiogenesis, edema, and invasion. A more recent study
by Batchelor et al. [73] showed that functional MRI parameters such as
vascular permeability based on dynamic contrast-enhanced MRI and
apparent diffusion coefficients determined by diffusion-weighted MRI
are useful in evaluating early response of GBM to a panTKI, AZD2171.
Other than the imagingmodalities mentioned above, power Doppler
ultrasound has also been applied to monitoring tumor vascular changes
induced by anti-EGFR erlotinib [74]. Recognizing the complexity and
the importance of the EGFR downstream signaling pathways, possibly
contributing to the mechanism of resistance to anti-EGFR, the capabil-
ity of imaging not only EGFR itself but, more importantly, the interplay
of EGFR and the downstream factors, will be the most challenging task.
Signal Transduction
What makes EGFRvIII more tumorigenic than the wt receptor? The
cytoplasmic (signaling) domain is the same for the wtEGFR and
EGFRvIII, and it has been proposed that altered kinetics of signaling
may explain the differences in oncogenic potential between the wt and
mutant EGFR [75,76]. Binding of ligand to the wtEGFR results in rapid
internalization of the receptor, followed by dephosphorylation and
degradation or recycling of the receptor [77]. Expression of EGFRvIII
results in a constitutive tyrosine phosphorylation of EGFRvIII. Because
EGFRvIII does not bind EGF, its internalization is slowed, promoting
a state of low-level continuous signaling from activated receptors at the
cell membrane [75]. Increased membrane persistence of activated re-
ceptors is known to favor mitogenic signaling [78]. A mechanistic ex-
planation for failure of EGFRvIII internalization and down-regulation
was provided by a study demonstrating that the reduced signal in-
tensity associated with EGFRvIII resulted in failure of EGFRvIII to
form complexes with Cbls, SETA or endophilin A1, which leads to
decreased dinternalization [76]. The altered kinetics of EGFRvIII acti-
vation could result in a distinct set of downstream signals compared with
the wtEGFR, and a number of studies have investigated signal transduc-
tion by the mutant EGFR. There are reports of constitutive activation
of the phosphatidylinositol 3-kinase/Akt pathway in cells expressing
EGFRvIII [79,80] leading to a down-regulation of p27 [81]. In ad-
dition, EGFRvIII-mediated activation of Ras [82] and extracellular
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signal–regulated kinases [83] has also been reported. Another study has
shown that SHP2 activates EGFRvIII but not wtEGFR through the
activation of mitogen-activated protein kinase (MAPK) [84]. The ex-
pression of EGFRvIII in U87MG cells leads to an increase in Bcl-XL
and resistance to apoptotic cell death in response to chemotherapy
[85]. Other studies have reported an important role for JNK acti-
vation in EGFRvIII signaling [86]. A recent study has proposed that
myristoylated alanine-rich protein kinase C substrate contributes to
EGFRvIII-mediated invasiveness [87].
Although the wtEGFR also activates these signals in response to
ligand, it does not seem to do so constitutively evenwhen overexpressed.
It has been proposed that signals generated by the wt receptor are ter-
minatedmore efficiently because ligand binding is an important mecha-
nism of receptor internalization and signal termination [88]. However,
a number of studies have shown that increased expression of the wt
receptor also overwhelms mechanisms for receptor internalization, de-
phosphorylation, and degradation and can result in persistent activation
of wt receptors [89,90]. Thus, questions about how the altered kinetics
of EGFRvIII translates into more oncogenic signals compared with the
wt receptor persist. In our previous study, wtEGFR and EGFRvIII were
inducibly expressed at similar levels in glioma cell lines followed by
gene expression profiling [18]. It was found that the expression of
wtEGFR in glioma cells resulted in increased expression of a wide spec-
trum of genes, including genes involved not only in proliferation but
also in growth suppression, immunemodulation,metabolism, and tran-
scription. Increased expression of the wt receptor without EGF stimu-
lation results in up-regulation of a total of 93 genes, suggesting that the
wt receptor also signals constitutively. If EGF is added to cells expressing
high levels of wtEGFR, there is a further increase in the number of genes
expressed to 159 [18]. As previous studies have suggested, gene induc-
tion by wtEGFR was more robust compared with EGFRvIII, which
generated weak induction of a small group of genes.
The frequent coexpression of wtEGFRwith EGFRvIII inGBM raises
the question of an interaction between the two. EGFRvIII may hetero-
dimerize with wtEGFR and coexpression of the two receptors enhances
cell proliferation and survival [91]. An additional mechanism was sug-
gested by the observation that EGFRvIII induces expression of heparin
binding epidermal growth factor (HB-EGF) and transforming growth
factor α (TGFα), ligands for the wtEGFR. Because EGFRvIII does
not bind ligand, this suggests that EGFRvIII generates an autocrine/
paracrine loop using the wtEGFR in glioma cells [18]. Autocrine loops,
in which both the receptor and the ligand are produced by the same
tumor cells, may be an important contributor to the growth autonomy
of cancer cells [92]. Coexpression of EGFR and TGFα is well docu-
mented in EGFR amplification–positive glioma as is the coexpression of
EGFR and HB-EGF [8,9]. The major experimental support for the sig-
nificance of autocrine loops is derived from studies showing that, whereas
expression of the receptor alone (EGFR) has a weak transforming effect
on cells, coexpression of ligand (TGFα) results in a robust increase in
transformation [93]. In addition, strategies aimed at neutralizing ligands
such as TGFα have been shown to decrease growth of cells harboring
such loops [8,94]. The experimental support for the biological significance
of this EGFRvIII-mediated autocrine loop was provided by demonstrat-
ing that antibodies to HB-EGF (but not TGFα) resulted in inhibition
of EGFRvIII mediated glioma cell proliferation (Figure 2). Further-
more, EGFRvIII expression correlated with HB-EGF expression in
GBM [18].
In addition toHB-EGFand TGFα, we found that EGFRvIII expres-
sion results in expression of EPH receptor A2 (EphA2), IL-8, mitogen-
activated protein kinase kinase kinase kinase 4 (MAP4K4), FOSL1,
epithelial membrane protein 1 (EMP1), and DUSP6, all of which are
known to influence oncogenic signaling pathways [18]. Previous studies
have established that EphA2 [18,95–99], FosL1-Fra1 [99,100], IL8/
CXCL8 [101,102], and EMP1 [103] have been detected in glioma or
glioma cell lines. IL-8/CXCL8 is a chemotactic factor that may play an
important role in angiogenesis and tumor development [104,105] and
is upregulated in PTEN-negative glioma [106]. The EphA2 is a re-
ceptor tyrosine kinase that is frequently overexpressed in cancer and
may play an important role in glioma [18,95–98,107, 108]. MAP4K4
(hepatocyte progenitor kinase-like/germinal center kinase-like kinase) is
broadly expressed in cancer and can modulate cellular transformation,
invasion, and Ras-mediated transformation [109,110]. Another gene,
DUSP6 (MKP3), is upregulated by Ras signaling [111,112] and by
mutant EGFR in glioma and lung cancer [18,113]. EMP1 is increased
in leiyomyoma [114] and may play a role in glioma [103]. FOS-like
antigen 1 (FosL1, Fra1) is linked to erlotinib sensitivity in glioma [115]
and is induced in response to the activation of Ras or β-catenin pathways
[116]. This molecular signature may hold important clues to EGFRvIII-
mediated tumorigencity [18], and further studies are needed to eluci-
date the biological significance of EGFRvIII-mediated gene induction
in glioma.
EGFRvIII and DNA Double-Strand Break Repair
Whereas the activation of proproliferative and antiapoptotic pathways
by EGFR is an established concept, recent reports reveal a novel link
between EGFR signaling and the repair of radiation-induced DNA
double-strand breaks (DSBs). It has been clear for quite some time
now that EGFR expression or activation correlates with the radio-
resistance of cells and tumors [117]. Monoclonal antibodies or small
molecule inhibitors targeting EGFR can increase sensitivity to ionizing
radiation (IR) [19,118–120]. A direct correlation has been shown to
exist between EGFR expression levels and radiation resistance in cells;
these results have subsequently been extended to human head and neck
carcinoma samples where a direct correlation has been demonstrated
between EGFR expression levels and poor prognosis [121–124]. That
EGFR may respond to radiation-induced DNA damage in a direct
manner was first indicated by reports showing that IR could induce
rapid and transient phosphorylation of EGFR [125–128]. The ramifi-
cations of radiation-induced EGFR activation remained unknown until
Dittmann et al. [129] demonstrated that IR induces the nuclear trans-
location of EGFR (in addition to its activation; Figure 3). While in the
nucleus, EGFR interacts with and stimulates the kinase activity of
the 5DNA-dependent protein kinase catalytic subunit (DNA-PKcs)
[130]. DNA-PKcs is a key enzyme in the nonhomologous end joining
Figure 2. EGFRvIII-HBEGF-wtEGFR autocrine loop generated by
EGFRvIII and mediated by HB-EGF. In this model, the combined ac-
tion of EGFRvIII plus wtEGFR generates the biological response.
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(NHEJ) pathway of DSB repair [131]; hence, the activation of DNA-
PKcs by EGFR results in proficient repair of DSBs and provides an
explanation for the increase in radioresistance conferred by EGFR.More
importantly, the anti-EGFR antibody, cetuximab, can inhibit EGFR
nuclear transport and interaction with DNA-PKcs, resulting in a radio-
sensizing effect [132], thereby validating the possibility of using anti-
EGFR therapy for radiosensitizing purposes. In retrospect, a physical
association between EGFR and DNA-PKcs had been demonstrated
by Bandyopadhyay et al. [133] more than 10 years back who postulated
that EGFRmay be important for the maintenance of DNA-PKcs in the
nucleus. In the past couple of years, a number of reports have recon-
firmed this link between EGFR signaling andDSB repair; many of these
reports indicate that signaling through the phosphatidylinositol 3-kinase
(PI3K)–Akt or MAPK pathways might also impinge on DNA-PK acti-
vation rather than the direct interaction between EGFR and DNA-PK
initially proposed by the group of Rodemann [19,119,120,134–137].
Contrary to the effect of wtEGFR, EGFRwithmutations in the tyrosine
kinase domain seem to have an inhibitory effect on DSB repair in lung
cancer cells, possibly because of a deficit in nuclear translocation of
these mutant forms of EGFR [119,120]. The most common deletion
mutant, EGFRvIII, occurs commonly in GBMs [138]. EGFRvIII lacks
the extracellular, ligand-binding domain but is constitutively active and
resistant to receptor internalization and attenuation. EGFRvIII is also
phosphorylated in response to IR and actually displays even higher levels
of IR-induced activation compared with the wt receptor [139]. We find
that EGFRvIII contributes to the radioresistance of glioma-relevant cells
and tumors by promoting the repair of DSBs vis-à-vis hyperactivation of
DNA-PKcs [19], similar to that reported for the wt receptor in lung
cancer cells. However, unlike observations in lung cancer cells, in the
context of murine astrocytes, human glioma cells, or orthotopic brain
tumors, we fail to observe any nuclear relocalization of EGFRvIII on
radiation [19] nor is there any evidence of nuclear localization of EGFR
in tissue arrays of human GBM samples (our unpublished data). It is
therefore plausible that, in the context of gliomas, specific signal cas-
cades emanating from the EGFRvIII receptor [138], rather than an
actual physical association between EGFRvIII andDNA-PK,might pro-
mote efficient DSB repair. Several lines of evidence indicate that whereas
ligand-activated EGFR stimulates both the RAS-RAF-MAPK and PI3K-
Akt pathways [138], EGFRvIII may preferentially activate the PI3K-Akt
pathway [140–142], and activation of the PI3K-Akt pathway by EGFR-
vIII may be more robust than by wtEGFR [139].We therefore speculate
that the increase in radioresistance conferred by the EGFRvIII may be
executed through the PI3-Akt pathway. Activated Akt prevents apop-
tosis by inhibiting proapoptotic factors such as BAD (BCL2 antagonist
of cell death) and procaspase-9 and stimulates cell proliferation [143] by
activating mammalian target of rapamycin [144]. The following reports
Figure 3. EGFR signaling and NHEJ. The binding of EGF or TGFα to EGFR activates the following pathways: (1) PI3K–Akt-1 pathway, (2) Ras/
RAF/MAPK/extracellular signal–regulated (ERK) pathway, and (3) signal transducer and activation of transcription (STAT) pathway (only the
PI3K–Akt-1 pathway is shown for simplicity). EGFRvIII, a common deletion mutant that lacks the ligand-binding extracellular domain, is consti-
tutively active and signals preferentially through the PI3K–Akt-1 pathway. In this pathway, activated PI3K phosphorylates phosphatidylinositol-
4,5-biphosphate (PIP2) generating phosphatidylinositol-3,4,5-triphosphate (PIP3). PIP3 anchors Akt-1 to the plasma membrane, where it is
phosphorylated by mammalian target of rapamycin complex 2 (mTORC2) and 3-phosphoinositide–dependent kinase 1 (PDK1). Activated
Akt-1 phosphorylates a variety of downstream targets that enhance proliferation and inhibit cell death. The PTEN tumor suppressor negatively
regulates PI3K–Akt-1 signaling by reversing PIP3 back to PIP2. Two models have been proposed to explain the connection between EGFR
and NHEJ. In one scenario, wtEGFR translocates into the nucleus in response to IR, interacts with DNA-PKcs (DNA-dependent protein kinase,
catalytic subunit), and stimulates its DNA repair activity (I). In another scenario, Akt-1 translocates into the nucleus in response to IR and inter-
actswithDNA-PKcs (II). Phosphorylation of Akt-1 byDNA-PKcspromotes survival (curved arrow) andwehypothesize that reciprocal phosphory-
lation of DNA-PKcs by Akt-1 might promote DSB repair through NHEJ.
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postulate that activated Akt may also play a role in the repair of DSBs. IR
stimulates the activation of Akt and its phosphorylation at threonine
308 and serine 473 [125,145]. Dampening of PI3K-Akt signaling using
small molecule inhibitors impairs DSB repair in GBM [135] and breast
cancer cells [146], whereas siRNA-mediated Akt knockdown impairs
DSB repair in cancer cells [137], and this results in radiation sensitivity.
Nevertheless, hyperactivation of the PIK-Akt pathway due to deletion
of PTEN promotes DSB repair and radiation survival [135]. We, too,
find that the PI3K inhibitor LY294002 can abrogate the proficient
DSB repair conferred by EGFRvIII overexpression and that expression
of a constitutively active version of Akt can mimic the effects of EGFR-
vIII overexpression on DSB repair in astrocytes [19]. Significantly, a re-
cent report demonstrated that Akt translocates to the nucleus on
irradiation and associates with DNA-PK at the sites of DSBs [147–
149]. Activation of DNA-PKcs involves its phosphorylation on serine/
threonine residues [130,131]. As Akt is a serine/threonine kinase, it is
possible that hyperactivation of DNA-PK by EGFRvIII might be medi-
ated by Akt (Figure 3). The putative connection among EGFRvIII, Akt,
and DNA-PKcs is worthy of detailed investigation in the future.
Concluding Comments
The identification of EGFR amplification and mutation in GBM has
led to important advances in demonstrating that the EGFR (in combi-
nation with other genetic alterations) is likely to play an important role
in the pathogenesis of this disease. GBMs are highly resistance to treat-
ment with radiation and chemotherapy and aberrant EGFR signaling
contributes to this resistance. Thus, the EGFR remains an attractive
target for therapeutic intervention in GBM, although initial attempts
to target the EGFR have not been effective in GBM. Furthermore, im-
portant progress has been made in detection of aberrant EGFR signal-
ing with improved neuropathological tools and advances in imaging.
However, a number of important questions remain unanswered, includ-
ing some fundamental questions. Activation of the EGFR seems to trig-
ger a diverse array of signals within the cell and identifying the key
downstream signals thatmediate specific biological responses such as cell
proliferation or motility remains a challenge. The increased oncogenic
potential of specific EGFR mutants such as EGFRvIII remains incom-
pletely understood, because even the wtEGFR has been shown to sig-
nal constitutively when overexpressed. Another question that deserves
further study is the effect of EGFR overexpression on downstream sig-
nal transduction. Previous studies have suggested that increased expres-
sion or activation of receptor tyrosine kinase signaling systems does
not necessarily lead to a simple amplification of downstream signals.
Thus, dose-dependent changes in both oncogene-induced downstream
signal transduction as well as biological responses have been reported
[150,151], and an improved understanding of downstream signaling
is likely to improve EGFR targeting in GBM.
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